国际巨头“扫货”中国管线,本土药企如何跨越“廉价资产”鸿沟?

21世纪经济报道
03 Jun

21世纪经济报道记者季媛媛上海报道继三生制药与辉瑞就PD-1/VEGF双特异性抗体达成总额高达60.5亿美元的授权协议后,百时美施贵宝(BMS)也宣布与BioNTech达成协议,共同开发和商业化BNT327(PM8002)。根据公开资料,百时美施贵宝将向BioNTech支付高达111亿美元的里程碑付款,以支持BNT327的全球开发和商业化。  根据协议,BMS将向BioNTech支付15亿美元的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10